Search Close


Holdings in Company

16th April 2012

The Company announces that it has received notification that Helium Special Situations Fund Limited has a beneficial interest in Scancell Holdings of 15,556,940 ordinary shares of 0.1 pence each which represents approximately 8.0 per cent of the issued capital of the Company.

For further information contact:


Scancell Holdings Plc

Dr Richard Goodfellow / Professor Lindy Durrant


+ 44 (0)20 7653 9850*

Newgate Threadneedle (Financial PR)

Guy McDougall/ Heather Armstrong


+ 44 (0)20 7653 9850

Zeus Capital - Nominated Adviser/Joint Broker

Ross Andrews/Tom Rowley


+ 44 (0)161 831 1512

XCAP - Joint Broker

Jon Belliss/ Adrian Kirk


+44 (0)207 101 7070


*calls to this number will reach Newgate Threadneedle, at Scancell’s instruction.

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and entered clinical trials in 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.

Webcasts, Interviews and Media Coverage

New Scancell chief sets out his vision to commercialise groundbreaking cancer treatments

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company.

Holloway says generating clinical data's a big focus for them in the near-term.

''Over the next two years we expect to see clinical readouts from two of our programmes - SCIB1 and Modi-1''.

''We'll be extending our pipeline particularly around Moditope with the Modi-3 programme, if we're successful with the grand challenge''.

''Then it's around looking at technical partnerships that will allow us to de-risk our developments''.

Thu, 15 Feb 2018 12:38:00

Scancell to work with Dutch firm on first product for Moditope cancer immuno-therapy platform

Dutch group ISA Pharmaceutical will incorporate its Amplivant technology into Modi-1, the first cancer treatment candidate being developed on the platform

Thu, 15 Feb 2018 15:00:00

Scancell drug receives positive write-up in leading journal as company updates on survival data

Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology

Mon, 12 Feb 2018 11:50:00